Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00075829 · FLOW

Participant flow

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) · Source last updated 2021-11-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Tandem autologous transplant plus thalidomide/dexamethasone (Thal-Dex) or observation (Obs) for standard risk patients PFS and OS did not differ between the Thal-Dex and the Obs arms and were thus pooled for analysis.
    id
    FG000
    title
    Auto-Auto Standard Risk
  2. description
    Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients
    id
    FG001
    title
    Auto-Allo Standard Risk
  3. description
    Tandem autologous transplant plus thalidomide/dexamethasone (Thal-Dex) or observation (Obs) for high risk patients PFS and OS did not differ between the Thal-Dex and the Obs arms and were thus pooled for analysis.
    id
    FG002
    title
    Auto-Auto High Risk
  4. description
    Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients
    id
    FG003
    title
    Auto-Allo High Risk
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        436
      2. group Id
        FG001
        num Subjects
        189
      3. group Id
        FG002
        num Subjects
        48
      4. group Id
        FG003
        num Subjects
        37
      type
      STARTED
    2. achievements
      1. comment
        Participants that were alive and free of disease progression at the end of follow-up (3 years)
        group Id
        FG000
        num Subjects
        178
      2. comment
        Participants that were alive and free of disease progression at the end of follow-up (3 years)
        group Id
        FG001
        num Subjects
        71
      3. comment
        Participants that were alive and free of disease progression at the end of follow-up (3 years)
        group Id
        FG002
        num Subjects
        14
      4. comment
        Participants that were alive and free of disease progression at the end of follow-up (3 years)
        group Id
        FG003
        num Subjects
        13
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        258
      2. group Id
        FG001
        num Subjects
        118
      3. group Id
        FG002
        num Subjects
        34
      4. group Id
        FG003
        num Subjects
        24
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Participants were enrolled between December 2003 and March 2007 from 37 different transplant centers.
Complete source fields
groups
  1. description
    Tandem autologous transplant plus thalidomide/dexamethasone (Thal-Dex) or observation (Obs) for standard risk patients PFS and OS did not differ between the Thal-Dex and the Obs arms and were thus pooled for analysis.
    id
    FG000
    title
    Auto-Auto Standard Risk
  2. description
    Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients
    id
    FG001
    title
    Auto-Allo Standard Risk
  3. description
    Tandem autologous transplant plus thalidomide/dexamethasone (Thal-Dex) or observation (Obs) for high risk patients PFS and OS did not differ between the Thal-Dex and the Obs arms and were thus pooled for analysis.
    id
    FG002
    title
    Auto-Auto High Risk
  4. description
    Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients
    id
    FG003
    title
    Auto-Allo High Risk
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        436
      2. group Id
        FG001
        num Subjects
        189
      3. group Id
        FG002
        num Subjects
        48
      4. group Id
        FG003
        num Subjects
        37
      type
      STARTED
    2. achievements
      1. comment
        Participants that were alive and free of disease progression at the end of follow-up (3 years)
        group Id
        FG000
        num Subjects
        178
      2. comment
        Participants that were alive and free of disease progression at the end of follow-up (3 years)
        group Id
        FG001
        num Subjects
        71
      3. comment
        Participants that were alive and free of disease progression at the end of follow-up (3 years)
        group Id
        FG002
        num Subjects
        14
      4. comment
        Participants that were alive and free of disease progression at the end of follow-up (3 years)
        group Id
        FG003
        num Subjects
        13
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        258
      2. group Id
        FG001
        num Subjects
        118
      3. group Id
        FG002
        num Subjects
        34
      4. group Id
        FG003
        num Subjects
        24
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Participants were enrolled between December 2003 and March 2007 from 37 different transplant centers.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice